Sandoz Canada received market authorization for Omnitrope in Canada. Omnitrope is the first biosimilar of a previously approved recombinant drug to be approved by Health Canada under Subsequent Entry Biologic (SEB). Omnitrope, a somatropin (rDNA origin) for injection, is approved for the long-term treatment of children with growth failure due to an inadequate secretion of endogenous growth hormone, and long-term replacement therapy in adults with growth hormone deficiency due to an underlying...